Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration
Authors
Keywords
Biosimilar, FYB201, Lucentis, Neovascular age-related macular degeneration, Ranibizumab
Journal
OPHTHALMOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-05-03
DOI
10.1016/j.ophtha.2021.04.031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab
- (2019) JACOPO GIULIANI et al. ANTICANCER RESEARCH
- Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective
- (2019) Ashish Sharma et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- The economic and humanistic burden of patients in receipt of current available therapies for nAMD
- (2018) Dena H Jaffe et al. Journal of Comparative Effectiveness Research
- Treatment for neovascular age related macular degeneration: The state of the art
- (2016) Chiara M. Eandi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
- (2016) Sharon D. Solomon et al. OPHTHALMOLOGY
- High Variation of Intravitreal Injection Rates and Medicare Anti–Vascular Endothelial Growth Factor Payments per Injection in the United States
- (2016) Jay C. Erie et al. OPHTHALMOLOGY
- METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2016) Leah N. Kim et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
- (2015) Karina Berg et al. OPHTHALMOLOGY
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
- (2014) Wan Ling Wong et al. Lancet Global Health
- A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
- (2013) Ilse Krebs et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial
- (2013) Laurent Kodjikian et al. OPHTHALMOLOGY
- Age-Related Macular Degeneration
- (2013) Lily K. Cheung et al. PHARMACOTHERAPY
- Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany
- (2012) Robert P. Finger et al. ACTA OPHTHALMOLOGICA
- Age-related macular degeneration
- (2012) Laurence S Lim et al. LANCET
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- (2012) Michael A. Singer et al. OPHTHALMOLOGY
- Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review
- (2011) Elena Prokofyeva et al. OPHTHALMIC RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now